These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33762178)

  • 21. Plasma Apixaban Levels in Patients Treated Off Label With the Lower Dose.
    Bhagirath VC; Chan N; Hirsh J; Ginsberg J; de Vries TAC; Eikelboom J
    J Am Coll Cardiol; 2020 Dec; 76(24):2906-2907. PubMed ID: 33303080
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation.
    Nagao T; Inden Y; Shimano M; Fujita M; Yanagisawa S; Kato H; Ishikawa S; Miyoshi A; Okumura S; Ohguchi S; Yamamoto T; Yoshida N; Hirai M; Murohara T
    Pacing Clin Electrophysiol; 2015 Feb; 38(2):155-63. PubMed ID: 25487164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon.
    Kaess BM; Ammar S; Reents T; Dillier R; Lennerz C; Semmler V; Grebmer C; Bourier F; Buiatti A; Kolb C; Deisenhofer I; Hessling G
    Am J Cardiol; 2015 Jan; 115(1):47-51. PubMed ID: 25456870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease.
    Eikelboom JW; Connolly SJ; Gao P; Paolasso E; De Caterina R; Husted S; O'Donnell M; Yusuf S; Hart RG
    J Stroke Cerebrovasc Dis; 2012 Aug; 21(6):429-35. PubMed ID: 22818021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter prospective cohort study to investigate the effectiveness and safety of apixaban in Japanese elderly atrial fibrillation patients (J-ELD AF Registry).
    Okumura K; Yamashita T; Suzuki S; Akao M;
    Clin Cardiol; 2020 Mar; 43(3):251-259. PubMed ID: 31737921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial.
    Ezekowitz JA; Lewis BS; Lopes RD; Wojdyla DM; McMurray JJ; Hanna M; Atar D; Cecilia Bahit M; Keltai M; Lopez-Sendon JL; Pais P; Ruzyllo W; Wallentin L; Granger CB; Alexander JH
    Eur Heart J Cardiovasc Pharmacother; 2015 Apr; 1(2):86-94. PubMed ID: 27533976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
    Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
    J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease.
    Schafer JH; Casey AL; Dupre KA; Staubes BA
    Ann Pharmacother; 2018 Nov; 52(11):1078-1084. PubMed ID: 29871510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secondary stroke prevention with apixaban in nonvalvular atrial fibrillation: A subgroup analysis of the STANDARD study.
    Yasaka M; Umeyama M; Kataoka H; Inoue H
    J Stroke Cerebrovasc Dis; 2020 Sep; 29(9):105034. PubMed ID: 32807446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry.
    Ruiz Ortiz M; Muñiz J; Raña Míguez P; Roldán I; Marín F; Asunción Esteve-Pastor M; Cequier A; Martínez-Sellés M; Bertomeu V; Anguita M;
    Europace; 2018 Oct; 20(10):1577-1583. PubMed ID: 29186393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial.
    Lopes RD; Alings M; Connolly SJ; Beresh H; Granger CB; Mazuecos JB; Boriani G; Nielsen JC; Conen D; Hohnloser SH; Mairesse GH; Mabo P; Camm AJ; Healey JS
    Am Heart J; 2017 Jul; 189():137-145. PubMed ID: 28625370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of direct oral anticoagulants in very elderly patients: a case report of apixaban in an ultracentenary patient.
    Manno G; Novo G; Corrado E; Coppola G; Novo S
    J Cardiovasc Med (Hagerstown); 2019 Jun; 20(6):403-405. PubMed ID: 30762659
    [No Abstract]   [Full Text] [Related]  

  • 33. Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?-A Systematic Review.
    de Vries TAC; Hirsh J; Xu K; Mallick I; Bhagirath VC; Eikelboom JW; Ginsberg JS; Kruger PC; Chan NC
    Thromb Haemost; 2020 Sep; 120(9):1323-1329. PubMed ID: 32668484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome, and percutaneous coronary intervention.
    Gumprecht J; Domek M; Lip GYH
    Expert Opin Drug Saf; 2019 Dec; 18(12):1119-1125. PubMed ID: 31580164
    [No Abstract]   [Full Text] [Related]  

  • 35. Influence of apixaban on antifactor Xa levels in a patient with acute kidney injury.
    Wendte J; Voss G; VanOverschelde B
    Am J Health Syst Pharm; 2016 Apr; 73(8):563-7. PubMed ID: 27045068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.
    Yao X; Shah ND; Sangaralingham LR; Gersh BJ; Noseworthy PA
    J Am Coll Cardiol; 2017 Jun; 69(23):2779-2790. PubMed ID: 28595692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apixaban in Patients with Atrial Fibrillation and Severe Renal Dysfunction: Findings from a National Registry.
    Elis A; Klempfner R; Gurevitz C; Gilady E; Goldenberg I
    Isr Med Assoc J; 2021 Jun; 23(6):353-358. PubMed ID: 34155848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stroke and Bleeding Risks in Patients with Atrial Fibrillation Treated with Reduced Apixaban Dose: A Real-Life Study.
    Salameh M; Gronich N; Stein N; Kotler A; Rennert G; Auriel E; Saliba W
    Clin Pharmacol Ther; 2020 Dec; 108(6):1265-1273. PubMed ID: 32558928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU Trial.
    Reynolds MR; Allison JS; Natale A; Weisberg IL; Ellenbogen KA; Richards M; Hsieh WH; Sutherland J; Cannon CP
    JACC Clin Electrophysiol; 2018 May; 4(5):580-588. PubMed ID: 29798783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation.
    Manzano-Fernández S; Andreu-Cayuelas JM; Marín F; Orenes-Piñero E; Gallego P; Valdés M; Vicente V; Lip GY; Roldán V
    Rev Esp Cardiol (Engl Ed); 2015 Jun; 68(6):497-504. PubMed ID: 25457087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.